ArticleCancer reports (Hoboken, N.J.)2026
Acute Gout Flare After Carboplatin/5-Fluorouracil for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. For locally advanced cases when upfront surgery or radiation are not feasible, a platinum agent (carboplatin or cisplatin) with 5-fluorouracil (carbo-5FU) and immunotherapy is the standard of care. We present the first documented case of acute gout flare in a HNSCC patient after initiation of carboplatin-5-fluorouracil. CASE: A 67-year-old male patient with a remote history of gout and recurrent HPV-associated oropharyngeal squamous cell carcinoma (OSCC) presented for evaluation and management of local recurrence. He underwent right tonsillectomy, chemoradiation, and naturopathic therapy over the past 9 years, but the OSCC recurred in the right neck. As the patient was deemed a poor surgical candidate and declined radiation therapy, he was counseled on treatment options and elected to proceed with palliative systemic carbo-5FU therapy but experienced an acute gout flare after cycle 1. Uric acid was checked and found to be elevated at 9.3. He then started prednisone, allopurinol, and intravenous hydration for gout control, and his initially elevated uric acid levels normalized over the next 5 weeks.
conclusionsOur case describes the first documented incidence of gout flare precipitated by carbo-5FU, but also demonstrates a successful pharmacological treatment approach to control chemotherapy-induced gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.